Methotrexate
DB00563
Approved Indication
Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic ag
1
Targets
0
Resistance Mutations
2
References
1DLS
Structure Loaded
Protein Targets
Mechanism of Action
Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.
Details
DrugBank ID
DB00563 ↗
Approval Date
1953-07-12
Molecular Weight
454.4393 g/mol
Drug Class
Other
ATC Codes
L04AX03, L01BA01
Synonyms
4-amino-10-methylfolic acid, Amethopterin, Methotrexat
PubChem
CID: 126941 ↗
ChEMBL
CHEMBL34259 ↗
SMILES
CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
ADMET Profile
Computing properties…
Drug References (DrugBank)